Kazia Therapeutics Ltd 6-K, filed Feb 24, 2023
Kazia Therapeutics Ltd (KZIA)
About this 6-K
Kazia Therapeutics Ltd filed this 6-K on February 24, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February, 2023
Commission File Number 000-29962
Kazia Therapeutics Limited
(Translation of registrant’s name into English)
Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☑ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On February 24, 2023, Kazia Therapeutics Limited (the “Company”), in connection with the reporting of its change in auditor pursuant to and in accordance with ASX Listing Rule 3.16.3, issued an ASX announcement titled, “Change In Auditor.” A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, into the Company’s registration statement on Form F-3 (File No. 333-259224).
EXHIBIT LIST
| Exhibit | Description | |
| 99.1 | ASX Announcement of Kazia Therapeutics Limited dated February 24, 2023 | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Kazia Therapeutics Limited (Registrant) |
| /s/ Karen Krumeich |
| Karen Krumeich |
| Chief Financial Officer |
| Date: 24 February 2023 |
Exhibit 99.1
ASX ANNOUNCEMENT
24 February 2023
CHANGE IN AUDITOR
Sydney, 24 February 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), (the Company), an oncology-focused drug development company, advises that in accordance with ASX Listing Rule 3.16.3, BDO Audit Pty Ltd (BDO) has been appointed as auditor of Kazia Therapeutics Limited, effective from the date of this announcement.
The change follows the resignation of Grant Thornton Audit Pty Ltd (Grant Thornton) as auditor of Kazia Therapeutics Limited in accordance with section 329(5) of the Corporations Act 2001 (Cth) (Corporations Act) and ASIC’s consent to the resignation.
The appointment of the new auditor of the Company was considered by the Board to be a matter of good corporate governance. Grant Thornton had held the position as auditor for a number of years, and accordingly it was deemed appropriate to conduct a tender process to seek a new auditor. The Company confirms that it has received a letter of resignation from Grant Thornton and has also received the consent of ASIC to their resignation.
BDO’s appointment is effective until the 2023 Annual General Meeting of the Company. In accordance with section 327C of the Corporations Act, a resolution will be put to shareholders and the 2023 Annual General Meeting to appoint BDO as the auditor of Kazia Therapeutics Limited.
The Board would like to take this opportunity to thank Grant Thornton for its assistance and services to the Company over their years of service.
ENDS
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed phase II study in glioblastoma reported promising signals of efficacy in 2021, and a pivotal study for registration, GBM AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data.
Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively.
Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno- oncology agents. A phase I study commenced recruitment in November 2021.
For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx.